Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age \>= 18 years~* 2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc fulfilled~* SSc disease onset (defined by first non-Raynaud symptom) within 7 years~* SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography (HRCT); Extent of fibrotic disease in the lung \>= 10%~* FVC \>= 40% of predicted normal~* Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal~Exclusion criteria:~* Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \>1.5 x ULN~* Bilirubin \>1.5 x ULN~* Creatinine clearance \<30 mL/min~* Airway obstruction (pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1)/FVC \<0.7)~* Other clinically significant pulmonary abnormalities~* Significant Pulmonary Hypertension (PH)~* Cardiovascular diseases~* More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring hospitalization or severe other ulcers~* Bleeding risk (such as predisposition to bleeding, fibrinolysis, full-dose anticoagulation, high dose antiplatelet therapy, history of hemorrhagic central nervous system (CNS) event within last year~* international normalised ratio (INR) \>2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by \>1.5 x ULN)~* History of thrombotic event within last year~* Clinical signs of malabsorption or needing parenteral nutrition~* Previous treatment with nintedanib or pirfenidone~* Treatment with prednisone \>10 mg/day, azathioprine, hydroxychloroquine, colchicine, D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and cyclosporine A, potassium para-aminobenzoate~* Unstable background therapy with either mycophenolate mofetil or methotrexate~* Previous or planned hematopoietic stem cell transplantation~* Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nintedanib (Type: EXPERIMENTAL): patient receives capsules containing nintedanib twice a day
- Placebo (Type: PLACEBO_COMPARATOR): patient receives capsules identical to those containing active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).